Re-Aim Therapeutics Overview
- Year Founded
-
2024
- Status
-
Private
- Employees
-
3
- Latest Deal Type
-
Seed
- Latest Deal Amount
-
$9.5M
- Investors
-
3
Re-Aim Therapeutics General Information
Description
Developer of targeted biologics designed to address autoimmune diseases by depleting pathogenic T-cell subsets involved in chronic inflammation and disease progression. The company offers integration of pathway signatures with membrane targets to identify precise T cells, applies drugging of functional epitopes within disease contexts, and combines antibody discovery expertise with advisory input, enabling healthcare providers and researchers to access selective therapies that improve disease management and expand treatment options for autoimmune conditions.
Contact Information
Website
www.re-aimtx.comCorporate Office
- Innovation Building, Old Campus Road
- Oxford
- England, United Kingdom
Corporate Office
- Innovation Building, Old Campus Road
- Oxford
- England, United Kingdom
Re-Aim Therapeutics Timeline
Re-Aim Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Seed Round | 18-May-2026 | $9.5M | Completed | Product Development | ||
| 1. Angel (individual) | 28-Mar-2025 | Completed | Startup |
Re-Aim Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series Seed | ||||||||
| Ordinary |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Re-Aim Therapeutics Signals
Re-Aim Therapeutics Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Oxford Science Enterprises | Venture Capital | Minority | ||
| Syncona | Venture Capital | Minority | ||
| NG Bio (UK) | Venture Capital | Minority |
Re-Aim Therapeutics FAQs
-
When was Re-Aim Therapeutics founded?
Re-Aim Therapeutics was founded in 2024.
-
Where is Re-Aim Therapeutics headquartered?
Re-Aim Therapeutics is headquartered in Oxford, United Kingdom.
-
What is the size of Re-Aim Therapeutics?
Re-Aim Therapeutics has 3 total employees.
-
What industry is Re-Aim Therapeutics in?
Re-Aim Therapeutics’s primary industry is Drug Discovery.
-
Is Re-Aim Therapeutics a private or public company?
Re-Aim Therapeutics is a Private company.
-
What is the current valuation of Re-Aim Therapeutics?
The current valuation of Re-Aim Therapeutics is .
-
What is Re-Aim Therapeutics’s current revenue?
The current revenue for Re-Aim Therapeutics is .
-
How much funding has Re-Aim Therapeutics raised over time?
Re-Aim Therapeutics has raised $9.8M.
-
Who are Re-Aim Therapeutics’s investors?
Oxford Science Enterprises, Syncona, and NG Bio (UK) have invested in Re-Aim Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process